.jpeg)
2026-07-23 05:37:53
Cabozantinib (Cabozantinib) capsules are a multi-target tyrosine kinase inhibitor approved for progressive, metastatic medullary thyroid cancer (MTC), inhibiting RET, MET, and VEGFR signaling pathways to control tumor progression.
2026-07-23 02:50:52
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor for ALK-positive advanced NSCLC with potent ALK inhibition and superior CNS penetration. This article covers its mechanism of action, therapeutic advantages, efficacy factors, and adverse effect management.
2026-07-23 02:43:41
In July 2026, the FDA approved subcutaneous isatuximab (Sarclisa) for multiple myeloma across three indications spanning newly diagnosed to relapsed/refractory disease. This article reviews pivotal trial data, recommended dosing, and key safety warnings.
2026-07-23 02:29:04
Pemigatinib is an FGFR inhibitor for FGFR2 fusion/rearrangement-positive cholangiocarcinoma. This article covers common adverse effects (hyperphosphatemia, alopecia, stomatitis), ophthalmologic monitoring requirements, and dose modification strategies for safe long-term treatment.
2026-07-23 02:21:07
Selpercatinib is a selective RET kinase inhibitor for RET fusion-positive NSCLC and RET-mutant medullary thyroid carcinoma. This guide addresses meal timing, twice-daily dosing, missed dose management, and key monitoring considerations during treatment.
2026-07-23 02:11:21
Mitotane is the cornerstone drug for adrenocortical carcinoma (ACC) treatment. This article covers initial dosing, target plasma concentration range (14–20 mg/L), monitoring frequency, and adverse effect management for safe and effective therapy.
2026-07-22 04:17:54
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates endogenous erythropoietin production by mimicking the physiological response to hypoxia, offering an injection-free treatment option for patients with chronic kidney disease-related anemia. This article systematically reviews its mechanism of action, clinical efficacy, and safety profile.
2026-07-22 04:06:31
Ponatinib and olverembatinib are both third-generation BCR-ABL tyrosine kinase inhibitors effective against the T315I gatekeeper mutation. This article provides a systematic comparison across target coverage, clinical efficacy, cardiovascular safety, and dosing strategies to inform treatment decisions.
2026-07-21 07:22:56
A balanced review of leflunomide-related eye symptoms, incidence, monitoring recommendations, and management strategies for rheumatoid arthritis patients.
2026-07-21 07:17:20
A structured overview of progression criteria, molecular profiling, and sequential treatment strategies following resistance to garsorasib in advanced NSCLC.
2026-07-20 07:28:12
Capivasertib is an oral AKT inhibitor with molecular formula C₂₁H₂₅ClN₆O₂, selectively binding to AKT protein to block PI3K/AKT signaling, used in precision therapy for breast cancer and other tumors.
2026-07-20 07:25:47
Avatrombopag is an oral thrombopoietin receptor agonist indicated for chronic liver disease-associated thrombocytopenia and chronic immune thrombocytopenia (ITP) in adults and children aged 1 year and older, promoting platelet production via bone marrow stimulation.
